927872-64-8Relevant articles and documents
Development of a green and sustainable manufacturing process for gefapixant citrate (MK-7264) Part 3: Development of a one-pot formylation-cyclization sequence to the diaminopyrimidine core
Basu, Kallol,Lehnherr, Dan,Martin, Gary E.,Desmond, Richard A.,Lam, Yu-Hong,Peng, Feng,Chung, John Y.L.,Arvary, Rebecca A.,Zompa, Michael A.,Zhang, Si-Wei,Liu, Jinchu,Dance, Zachary E.X.,Larpent, Patrick,Cohen, Ryan D.,Guzman, Francisco J.,Rogus, Nicholas J.,Di Maso, Michael J.,Ren, Hong,Maloney, Kevin M.
, p. 2462 - 2477 (2020/11/18)
The development of a safe, robust, and efficient manufacturing route for the synthesis of diaminopyrimidine 1, a key intermediate to gefapixant citrate (MK-7264), is described. A full mechanistic understanding of the cyclization step in the presence of guanidine was established by performing isotopic labeling experiments and identification of impurities. Guided by the mechanistic understanding, further attempts to modify the cyclization reaction by employing additives to reduce the triazine (9) formation and guanidine loading will also be presented. This newly developed method delivered compound 1 in 88-94% yield on a commercial scale and addressed the shortcomings of the early synthetic route including high PMI, low atom economy, long cycle-time, and multiple purifications to achieve the desired quality.
Identification and SAR of novel diaminopyrimidines. Part 1: The discovery of RO-4, a dual P2X3/P2X2/3 antagonist for the treatment of pain
Carter, David S.,Alam, Muzaffar,Cai, Haiying,Dillon, Michael P.,Ford, Anthony P.D.W.,Gever, Joel R.,Jahangir, Alam,Lin, Clara,Moore, Amy G.,Wagner, Paul J.,Zhai, Yansheng
scheme or table, p. 1628 - 1631 (2009/11/30)
P2X purinoceptors are ligand-gated ion channels whose endogenous ligand is ATP. Both the P2X3 and P2X2/3 receptor subtypes have been shown to play an important role in the regulation of sensory function and dual P2X3/P2X2/3 antagonists offer significant potential for the treatment of pain. A high-throughput screen of the Roche compound collection resulted in the identification of a novel series of diaminopyrimidines; subsequent optimization resulted in the discovery of RO-4, a potent, selective and drug-like dual P2X3/P2X2/3 antagonist.
Diaminopyrimidines as P2X3 and P2X2/3 modulators
-
Page/Page column 17, (2008/12/08)
Compounds and methods for treating diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the compounds being of formula (I): wherein R1, R2, R3 and R4 are as defined herein.